In Situ Assembly of Fluorogenic RNA for Screening Natural Anti‐Liver Fibrosis Products via Dynamic Visualization of COL1A1 mRNA
Advanced Science · 2025
DOI: 10.1002/advs.202502850 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Rui Bai und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Materials Science and Engineering, Suzhou University of Science and Technology, Kerui Road, Suzhou, 215009, P. R. China. Hauptthemen laut MEDLINE: Liver Cirrhosis, RNA, Messenger, Collagen Type I. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China.
Abstract (Originalsprache)
Liver fibrosis, a critical precursor to cirrhosis and a leading cause of mortality, highlights the urgent need for the identification of effective therapeutics. Activation of hepatic stellate cells (HSCs) is a key process in liver fibrosis. This study presents a live‐cell drug‐screening approach that specifically targets fibrosis‐associated collagen type I alpha 1 ( COL1A1 ) mRNA in activated HSCs through the use of fluorogenic RNA self‐assembly. It employs a dual‐probe system to construct an RNA Mango II structure, which upon binding with COL1A1 mRNA, facilitates activation of the TO1‐Biotin fluorophore, thereby enabling the visualization of mRNA to indicate HSC activation levels. Through the application of a high throughput live‐cell screening system, dihydrotanshinone I (DHT) is identified as potent leading antifibrotic compound, evidenced by its inhibitory effects on COL1A1 mRNA expression. The therapeutic efficacy of DHT is further substantiated by monitoring COL1A1 mRNA dynamics following treatment. In vivo studies demonstrates the sustained administration of DHT significantly ameliorated liver fibrosis in mice models. This method offers a simple, cost‐effective approach of visualizing RNA dynamics and conducting drug screening in live cells, presenting a significant potential for the development of hepatic fibrosis therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Materials Science and Engineering, Suzhou University of Science and Technology, Kerui Road, Suzhou, 215009, P. R. China.
- State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 210009, P. R. China.
- Department of Chemical and Biomolecular Engineering, National University of Singapore, Singapore, 117585, Singapore.
ORCID-Profile: Bin Liu
Förderung
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
Zitieren
APA
Bai, R., Zhu, L. Z., Shao, C., Yin, Z., Liu, Q., Gu, Y., & Liu, B. (2025). In Situ Assembly of Fluorogenic RNA for Screening Natural Anti‐Liver Fibrosis Products via Dynamic Visualization of COL1A1 mRNA. Advanced Science. https://doi.org/10.1002/advs.202502850
Vancouver
Bai R, Zhu LZ, Shao C, Yin Z, Liu Q, Gu Y, et al. In Situ Assembly of Fluorogenic RNA for Screening Natural Anti‐Liver Fibrosis Products via Dynamic Visualization of COL1A1 mRNA. Advanced Science. 2025. doi:10.1002/advs.202502850
BibTeX
@article{Bai2025,
author = {Bai, Rui and Zhu, Li-Zeng and Shao, Changfa and Yin, Zheng and Liu, Qun and Gu, Yu and Liu, Bin},
title = {In Situ Assembly of Fluorogenic RNA for Screening Natural Anti‐Liver Fibrosis Products via Dynamic Visualization of COL1A1 mRNA},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202502850}
}
EUVIMED